Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line

1. W. A. Denny, Emerging DNA topisomerase inhibitors as anticancer drugs, Expert Opin. Emerg. Drugs 9 (2004) 105-133; DOI: 10.1517/eoed.9.1.105.32948.10.1517/eoed.9.1.105.3294815155139Search in Google Scholar

2. L. F. Liu, DNA topoisomerase poisons as antitumor drugs, Annu. Rev. Biochem. 58 (1989) 351-375; DOI: 10.1146/annurev.bi.58.070189.002031.10.1146/annurev.bi.58.070189.0020312549853Search in Google Scholar

3. G. Takemura and H. Fujiwara, Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management, Prog. Cardiovasc. Dis. 49 (2007) 330-352; DOI: 10.1016/j.pcad.2006.10.002.10.1016/j.pcad.2006.10.00217329180Search in Google Scholar

4. S. Hitchcock-Bryan, R. Gelber, J. R. Cassady and S. E. Sallan, The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia, Med. Pediatr. Oncol. 14 (1986) 211-215; DOI: http://dx.doi.org/10.1002/mpo.2950140405.10.1002/mpo.29501404053462467Search in Google Scholar

5. T. Feridooni, A. Hotchkiss, S. Remley-Carr, Y. Saga and K. B. S. Pasumarthi, Cardiomyocyte specific ablation of p53 is not sufficient to block doxorubicin induced cardiac fibrosis and associated cytoskeletal changes, PLoS ONE 6 (2011) e22801; DOI:10.1371/journal.pone.0022801.10.1371/journal.pone.0022801314576521829519Search in Google Scholar

6. X. Z. Han, S. Gao, Y. N. Cheng, Y. Z. Sun, W. Liu, L. L. Tang and D. M. Ren, Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes, Biosci. Trends 6 (2012) 19-25; DOI: 10.5582/bst.2012.v6.1.19.10.5582/bst.2012.v6.1.1922426099Search in Google Scholar

7. B. Glimelius, Benefit-risk assessment of irinotecan in advanced colorectal cancer, Drug Saf. 28 (2005) 417-433; DOI: http://dx.doi.org/10.2165/00002018-200528050-00005.10.2165/00002018-200528050-0000515853443Search in Google Scholar

8. J. Weekes, A. K.-Y. Lam, S. Sebesan and Y.-H. Ho, Irinotecan therapy and molecular targets in colorectal cancer: a systemic review, World J. Gastroenterol. 15 (2009) 3597-3602; DOI: http://dx.doi.org/10.3748/wjg.15.3597.10.3748/wjg.15.3597272123219653336Search in Google Scholar

9. G. Minotti, P. Menna, E. Salvatorelli, G. Cairo and L. Gianni, Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity, Pharmacol. Rev. 56 (2004) 185-229; DOI: 10.1124/pr.56.2.6.10.1124/pr.56.2.615169927Search in Google Scholar

10. R. Nithipongvanitch, W. Ittarat, M. P. Cole, J. Tangpong, D. K. S. Clair and T. D. Oberley, Mitochondrial and nuclear p53 localization in cardiomyocytes: redox modulation by doxorubicin (Adriamycin)?, Antioxid. Redox Signal. 9 (2007) 1001-1008; DOI:10.1089/ars.2007.1632.10.1089/ars.2007.163217508921Search in Google Scholar

11. E. H. Herman and V. J. Ferrans, Amelioration of chronic anthracycline cardiotoxicity by ICRF- -187 and other compounds, Cancer Treat Rev. 14 (1987) 225-259; DOI: 10.1016/0305-7372(87) 90011-9.Search in Google Scholar

12. S. M. Swain, F. S. Whaley, M. C. Gerber, M. S. Ewer, J. R. Bianchine and R. A. Gams, Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy, J. Clin. Oncol. 15 (1997) 13331340.Search in Google Scholar

13. S. M. Swain and P. Vici, The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review, J. Cancer Res. Clin. Oncol. 130 (2004) 1-7; DOI: 10. 1007/s00432-003-0498-7.10.1007/s00432-003-0498-714564513Search in Google Scholar

14. M. S. Wolin, Interactions of oxidants with vascular signaling systems, Arterioscl. Throm. Vas.Biol. 20 (2000) 1430-1442; DOI: 10.1161/01.ATV.20.6.1430.10.1161/01.ATV.20.6.1430Search in Google Scholar

15. D. B. Sawyer, R. Fukazawa, M. A. Arstall and R. A. Kelly, Daunorubicin-induced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane, Circ. Res. 84 (1999) 257-65; DOI: 10.1161/01.RES.84.3.257.10.1161/01.RES.84.3.257Search in Google Scholar

16. J. Bierau, R. Leen, A. H. van Gennip, H. N. Caron and A. B. P. van Kuilenburg, Determination of the deoxycytidine kinase activity in cell homogenates with a non-radiochemical assay using reversed- phase high performance liquid chromatography; Identification of a novel metabolite of 2-chlorodeoxyadenosine, J. Chromatogr. B 805 (2004) 339-346; DOI: 10.1016/j.jchromb.2004.03.036.10.1016/j.jchromb.2004.03.03615135110Search in Google Scholar

17. B. Diop-Frimpong, V. P. Chauhan, S. Krane, Y. Boucher and R. K. Jain, Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors, Proc. Natl. Acad. Sci. USA 108 (2011) 2909-2914; DOI: 10.1073/pnas.1018892108.10.1073/pnas.1018892108304111521282607Search in Google Scholar

18. C. E. Runyan, H. W. Schnaper and A.-C. Poncelet, The role of internalization in transforming growth factor beta1-induced Smad2 association with Smad anchor for receptor activation (SARA) and Smad2-dependent signaling in human mesangial cells, J. Biol. Chem. 280 (2005) 8300-8308; DOI: 10.1074/jbc.M407939200.10.1074/jbc.M40793920015613484Search in Google Scholar

19. K. Tamaki, S. Okuda, T. Ando, T. Iwamoto, M. Nakayama and M. Fujishima, TGF-beta 1 in glomerulosclerosis and interstitial fibrosis of adriamycin nephropathy, Kidney Int. 45 (1994) 525-536. 10.1038/ki.1994.688164441Search in Google Scholar